Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) PT at $8.50

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been assigned an average rating of “Hold” from the five research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $8.50.

XFOR has been the topic of several research reports. Guggenheim initiated coverage on X4 Pharmaceuticals in a research note on Monday, March 9th. They set a “buy” rating and a $12.00 price target on the stock. Wall Street Zen upgraded X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research report on Friday, March 27th.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ XFOR opened at $4.29 on Thursday. The stock has a 50 day simple moving average of $3.82 and a 200-day simple moving average of $3.74. X4 Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $6.63. The company has a current ratio of 10.16, a quick ratio of 9.98 and a debt-to-equity ratio of 0.41. The company has a market cap of $390.05 million, a PE ratio of -0.99 and a beta of 0.32.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. The business had revenue of $2.57 million during the quarter, compared to analyst estimates of $1.68 million. On average, equities research analysts forecast that X4 Pharmaceuticals will post -0.68 EPS for the current year.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Kingdon Capital Management L.L.C. increased its holdings in X4 Pharmaceuticals by 300.0% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock valued at $3,192,000 after buying an additional 700,000 shares during the period. Rosalind Advisors Inc. bought a new stake in X4 Pharmaceuticals in the 3rd quarter valued at $5,283,000. Palumbo Wealth Management LLC bought a new stake in X4 Pharmaceuticals in the 3rd quarter valued at $326,000. Susquehanna Portfolio Strategies LLC bought a new stake in X4 Pharmaceuticals in the 4th quarter valued at $173,000. Finally, Hudson Bay Capital Management LP bought a new stake in X4 Pharmaceuticals in the 4th quarter valued at $129,000. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.